AstraZeneca Income from Continuous Operations 2010-2024 | AZN
AstraZeneca annual/quarterly income from continuous operations history and growth rate from 2010 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
- AstraZeneca income from continuous operations for the quarter ending September 30, 2024 was $1.433B, a 3.99% increase year-over-year.
- AstraZeneca income from continuous operations for the twelve months ending September 30, 2024 was $6.500B, a 10.08% increase year-over-year.
- AstraZeneca annual income from continuous operations for 2023 was $5.961B, a 81.02% increase from 2022.
- AstraZeneca annual income from continuous operations for 2022 was $3.293B, a 2763.48% increase from 2021.
- AstraZeneca annual income from continuous operations for 2021 was $0.115B, a 96.34% decline from 2020.
AstraZeneca Annual Income from Continuous Operations
(Millions of US $) |
| 2023 |
$5,961 |
| 2022 |
$3,293 |
| 2021 |
$115 |
| 2020 |
$3,144 |
| 2019 |
$1,227 |
| 2018 |
$2,050 |
| 2017 |
$2,868 |
| 2016 |
$3,406 |
| 2015 |
$2,826 |
| 2014 |
$1,235 |
| 2013 |
$2,571 |
| 2012 |
$6,270 |
| 2011 |
$9,950 |
| 2010 |
$8,081 |
| 2009 |
$7,544 |
AstraZeneca Quarterly Income from Continuous Operations
(Millions of US $) |
| 2024-09-30 |
$1,433 |
| 2024-06-30 |
$1,928 |
| 2024-03-31 |
$2,180 |
| 2023-12-31 |
$959 |
| 2023-09-30 |
$1,378 |
| 2023-06-30 |
$1,820 |
| 2023-03-31 |
$1,804 |
| 2022-12-31 |
$903 |
| 2022-09-30 |
$1,642 |
| 2022-06-30 |
$360 |
| 2022-03-31 |
$388 |
| 2021-12-31 |
$-346 |
| 2021-09-30 |
$-1,651 |
| 2021-06-30 |
$550 |
| 2021-03-31 |
$1,562 |
| 2020-12-31 |
$1,005 |
| 2020-09-30 |
$651 |
| 2020-06-30 |
$738 |
| 2020-03-31 |
$750 |
| 2019-12-31 |
$277 |
| 2019-09-30 |
$280 |
| 2019-06-30 |
$107 |
| 2019-03-31 |
$563 |
| 2018-12-31 |
$1,009 |
| 2018-09-30 |
$406 |
| 2018-06-30 |
$319 |
| 2018-03-31 |
$316 |
| 2017-12-31 |
$1,261 |
| 2017-09-30 |
$649 |
| 2017-06-30 |
$446 |
| 2017-03-31 |
$512 |
| 2016-12-31 |
$1,817 |
| 2016-09-30 |
$995 |
| 2016-06-30 |
$-31 |
| 2016-03-31 |
$625 |
| 2015-12-31 |
$808 |
| 2015-09-30 |
$770 |
| 2015-06-30 |
$696 |
| 2015-03-31 |
$552 |
| 2014-12-31 |
$-321 |
| 2014-09-30 |
$253 |
| 2014-06-30 |
$797 |
| 2014-03-31 |
$506 |
| 2013-12-31 |
$-520 |
| 2013-09-30 |
$1,248 |
| 2013-06-30 |
$831 |
| 2013-03-31 |
$1,012 |
| 2012-12-31 |
$1,520 |
| 2012-09-30 |
$1,519 |
| 2012-06-30 |
$1,604 |
| 2012-03-31 |
$1,627 |
| 2011-12-31 |
$1,493 |
| 2011-09-30 |
$3,485 |
| 2011-06-30 |
$2,123 |
| 2011-03-31 |
$2,915 |
| 2010-12-31 |
$1,632 |
| 2010-09-30 |
$1,554 |
| 2010-06-30 |
$2,116 |
| 2010-03-31 |
$2,777 |
| 2009-12-31 |
$1,562 |
| 2009-09-30 |
$2,115 |
| 2009-06-30 |
$1,707 |
| 2009-03-31 |
$2,144 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$203.493B |
$45.811B |
|
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
|
